Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.
Empirico has raised $45.2M in total funding. The most recent round was Series B. The last funding was announced in March 2023.
Empirico's investors include DCVC Bio, Ionis Pharmaceuticals, Neotribe Ventures.
Empirico is headquartered in San Diego, United States.
Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.
Empirico is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Empirico — Funding & Investors." VCBacked, March 20, 2023, https://www.vcbacked.co/company/empirico. Accessed August 6, 2026.
VCBacked. (2023). Empirico — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/empirico
{{cite web |title=Empirico — Funding & Investors |url=https://www.vcbacked.co/company/empirico |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated